Första försökspersonen doserad i klinisk fas I-studie med laquinimod ögondroppar
10 déc. 2021 02h30 HE
|
Active Biotech
Lund, 10 december 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) tillkännager idag att den första försökspersonen har doserats i den kliniska fas I-studien med den nyutvecklade ögondroppsformuleringen...
First subject dosed in phase I clinical study with eye-drop formulation of laquinimod
10 déc. 2021 02h30 HE
|
Active Biotech
Lund, December 10, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first subject has been dosed in the phase I clinical study of the newly developed eye-drop formulation of the...
Data som visar att naptumomab estafenatox förstärker CAR-T-cellers effekt presenterades av Active Biotechs partner NeoTX vid SITC 2021
30 nov. 2021 09h00 HE
|
Active Biotech
Lund, 30 november 30 2021 – Active Biotech (NASDAQ STOCKHOLM: ACTI) och samarbetspartnern NeoTX meddelar idag att prekliniska data för naptumomab, vilka visar på ökad effektivitet av CAR-T-celler,...
Data on naptumomab estafenatox enhancing CAR-T cells potency presented by Active Biotech’s partner NeoTX at SITC 2021
30 nov. 2021 09h00 HE
|
Active Biotech
Lund, Sweden — November 30, 2021 – Active Biotech and its partner NeoTX announced that the preclinical data on naptumomab enhancing the potency of CAR-T cells was presented on Nov 12th at the Society...
Active Biotechs partner NeoTX presenterar vid det årliga mötet i Society for Immunotherapy of Cancer (SITC)
09 nov. 2021 08h00 HE
|
Active Biotech
Lund, November 9, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) och samarbetspartnern NeoTX meddelar idag att naptumomab estafenatox (naptumomab, NAP) kommer att presenteras på The Society för...
Active Biotech’s partner NeoTX to Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
09 nov. 2021 08h00 HE
|
Active Biotech
Lund, November 9, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today a presentation on naptumomab estafenatox (naptumomab, NAP), at the Society for Immunotherapy of...
Nya prekliniska data kring tasquinimod kommer att presenteras på det årliga mötet i American Society of Hematology (ASH)
04 nov. 2021 09h00 HE
|
Active Biotech
Lund, 4 november 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) meddelade idag att två abstrakt med nya prekliniska data kring tasquinimod, en småmolekylar immunmodulator, har blivit accepterade för...
New preclinical data on tasquinimod will be presented at the annual meeting of American Society of Hematology (ASH)
04 nov. 2021 09h00 HE
|
Active Biotech
Lund, November 4, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that two abstracts with new preclinical data on tasquinimod, a small molecule immunomodulator, have been accepted for...
Active Biotech Delårsrapport januari - september 2021
04 nov. 2021 03h30 HE
|
Active Biotech
”Vi har fått de första uppmuntrande resultaten från den pågående tasquinimod-studien i multipelt myelom och startat en ny kombinationsstudie med naptumomab och docetaxel i lungcancer” TREDJE...
Active Biotech Interim report January - September 2021
04 nov. 2021 03h30 HE
|
Active Biotech
“We have seen the first encouraging results from the ongoing tasquinimod trial in multiple myeloma and started a new combination study with naptumomab and docetaxel in lung cancer” THIRD...